Trial Profile
Taxanes combined with Apatinib mesylate in the treatment for patients with advanced breast cancer: an open-label, single-arm, single-center clinical research
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2016
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 12 Oct 2016 New trial record